Lysophosphatidic acid signaling in ovarian cancer

References

• Tigyi G. Aiming drug discovery at lysophosphatidic acid targets. Br J Pharmacol 2010;161:241–70
   PubMed Web of Science ®Google Scholar
• Xu Y, Shen Z, Wiper DW, et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 1998;280:719–23
   PubMed Web of Science ®Google Scholar
• Bese T, Barbaros M, Baykara E, et al. Comparison of total plasma lysophosphatidic acid and serum CA-125 as a tumor marker in the diagnosis and follow-up of patients with epithelial ovarian cancer. J Gynecol Oncol 2010;21:248–54
   PubMed Web of Science ®Google Scholar
• Jesionowska A, Cecerska E, Dolegowska B. Methods for quantifying lysophosphatidic acid in body fluids: a review. Anal Biochem 2014;453:38–43
   PubMed Web of Science ®Google Scholar
• Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nature 2003;3:582–91
   Web of Science ®Google Scholar
• Noguchi K, Herr D, Mutoh T, Chun J. Lysophosphatidic acid (LPA) and its receptors. Curr Opin Pharmacol 2009;9:15–23
   PubMed Web of Science ®Google Scholar
• Lin ME, Herr DR, Chun J. Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance. Prostaglandins Other Lipid Mediat 2010;91:130–8
   PubMed Web of Science ®Google Scholar
• Goetzl EJ, Dolezalova H, Kong Y, et al. Distinctive expression and functions of the type 4 endothelial differentiation gene-encoded G protein-coupled receptor for lysophosphatidic acid in ovarian cancer. Cancer Res 1999;59:5370–5
   PubMed Web of Science ®Google Scholar
• Wang P, Wu X, Chen W, et al. The lysophosphatidic acid (LPA) receptors their expression and significance in epithelial ovarian neoplasms. Gynecol Oncol 2007;104:714–20
   PubMed Web of Science ®Google Scholar
• Yu S, Murph MM, Lu Y, et al. Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst 2008;100:1630–42
   PubMed Web of Science ®Google Scholar
• Wang GL, Wen ZQ, Xu WP, et al. Inhibition of lysophosphatidic acid receptor-2 expression by RNA interference decreases lysophosphatidic acid-induced urokinase plasminogen activator activation, cell invasion, and migration in ovarian cancer SKOV-3 cells. Croat Med J 2008;49:175–81
   PubMed Web of Science ®Google Scholar
• Fujita T, Miyamoto S, Onoyama I, et al. Expression of lysophosphatidic acid receptors and vascular endothelial growth factor mediating lysophosphatidic acid in the development of human ovarian cancer. Cancer Lett 2003;192:161–9
   PubMed Web of Science ®Google Scholar
• Leng R, Zha L, Tang L. MiR-718 represses VEGF and inhibits ovarian cancer cell progression. FEBS Lett 2014;588:2078–86
   PubMed Web of Science ®Google Scholar
• Hu YL, Tee MK, Goetzl EJ, et al. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst 2001;93:762–8
   PubMed Web of Science ®Google Scholar
• Lee J, Park SY, Lee EK, et al. Activation of hypoxia-inducible factor-1alpha is necessary for lysophosphatidic acid-induced vascular endothelial growth factor expression. Clin Cancer Res 2006;12:6351–8
   PubMed Web of Science ®Google Scholar
• Song Y, Wu J, Oyesanya RA, et al. Sp-1 and c-Myc mediate lysophosphatidic acid-induced expression of vascular endothelial growth factor in ovarian cancer cells via a hypoxia-inducible factor-1-independent mechanism. Clin Cancer Res 2009;15:492–501
   PubMed Web of Science ®Google Scholar
• Dutta S, Wang FQ, Wu HS, et al. The NF-κB pathway mediates lysophosphatidic acid (LPA)-induced VEGF signaling and cell invasion in epithelialovarian cancer (EOC). Gynecol Oncol 2011;123:129–37
   PubMed Web of Science ®Google Scholar
• So J, Wang FQ, Navari J, et al. LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2). Gynecol Oncol 2005;97:870–8
   PubMed Web of Science ®Google Scholar
• Wang FQ, Barfield E, Dutta S, et al. VEGFR-2 silencing by small interference RNA (siRNA) suppresses LPA-induced epithelial ovarian cancer (EOC) invasion. Gynecol Oncol 2009;115:414–23
   PubMed Web of Science ®Google Scholar
• Wong C, Wellman TL, Lounsbury KM. VEGF and HIF-1alpha expression are increased in advanced stages of epithelial ovarian cancer. Gynecol Oncol 2003;91:513–7
   PubMed Web of Science ®Google Scholar
• Bermudez Y, Yang H, Saunders BO, et al. VEGF- and LPA-induced telomerase in human ovarian cancer cells is Sp1-dependent. Gynecol Oncol 2007;106:526–37
   PubMed Web of Science ®Google Scholar
• Zhang W, Ling D, Tan J, et al. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance. Oncol Rep 2013;29:637–45
   PubMed Web of Science ®Google Scholar
• Estrella VC, Eder AM, Liu S, et al. Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38MAPK pathway. Int J Oncol 2007;31:441–9
   PubMed Web of Science ®Google Scholar
• Li H, Ye X, Mahanivong C, et al. Signaling mechanisms responsible for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells. J Biol Chem 2005;280:10564–71
   PubMed Web of Science ®Google Scholar
• Mahanivong C, Chen HM, Yee SW, et al. Protein kinase Ca-CARMA3 signaling axis links Ras to NF-κB for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells. Oncogene 2008;27:1273–80
   PubMed Web of Science ®Google Scholar
• Hu X, Li D, Zhang W, et al. Matrix metalloproteinase-9 expression correlates with prognosis and involved in ovarian cancer cell invasion. Arch Gynecol Obstet 2012;286:1537–43
   PubMed Web of Science ®Google Scholar
• Grelewski PG, Bar JK. The role of p53 protein and MMP-2 tumor/stromal cells expression on progressive growth of ovarian neoplasms. Cancer Invest 2013;31:472–9
   PubMed Web of Science ®Google Scholar
• Sakata K, Shigemasa K, Nagai N, Ohama K. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. Int J Oncol 2000;17:673–81
   PubMed Web of Science ®Google Scholar
• Coticchia CM, Curatolo AS, Zurakowski D, et al. Urinary MMP-2 and MMP-9 predict the presence of ovarian cancer in women with normal CA125 levels. Gynecol Oncol 2011;123:295–300
   PubMed Web of Science ®Google Scholar
• Li LN, Zhou X, Gu Y, Yan J. Prognostic value of MMP-9 in ovarian cancer: a meta-analysis. Asian Pac J Cancer Prev 2013;14:4107–13
   PubMed Web of Science ®Google Scholar
• Do TV, Symowicz JC, Berman DM, et al. Lysophosphatidic acid down-regulates stress fibers and up-regulates pro-matrix metalloproteinase-2 activation in ovarian cancer cells. Mol Cancer Res 2007;5:121–31
   PubMed Web of Science ®Google Scholar
• Fishman DA, Liu Y, Ellerbroek SM, Stack MS. Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer Res 2001;61:3194–9
   PubMed Web of Science ®Google Scholar
• Liu Y, Burkhalter R, Symowicz J, et al. Lysophosphatidic acid disrupts junctional integrity and epithelial cohesion in ovarian cancer cells. J Oncol 2012;2012:501492
   PubMedGoogle Scholar
• Gil OD, Lee C, Ariztia EV, et al. Lysophosphatidic acid (LPA) promotes E-cadherin ectodomain shedding and OVCA429 cell invasion in an uPA-dependent manner. Gynecol Oncol 2008;108:361–9
   PubMed Web of Science ®Google Scholar
• Wang FQ, Fisher J, Fishman DA. MMP-1-PAR1 axis mediates LPA-induced epithelial ovarian cancer (EOC) invasion. Gynecol Oncol 2011;120:247–55
   PubMed Web of Science ®Google Scholar
• Sengupta S, Kim KS, Berk MP, et al. Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion. Oncogene 2007;26:2894–901
   PubMed Web of Science ®Google Scholar
• Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J 1998;12:1063–73
   PubMed Web of Science ®Google Scholar
• Gu P, Su Y, Guo S, et al. Over-expression of COX-2 induces human ovarian cancer cells (CAOV-3) viability, migration and proliferation in association with PI3-k/Akt activation. Cancer Invest 2008;26:822–9
   PubMed Web of Science ®Google Scholar
• Yoshida A, Sarian LO, Andrade LA, et al. Cell proliferation activity unrelated to COX-2 expression in ovarian tumors. Int J Gynecol Cancer 2007;17:607–14
   PubMed Web of Science ®Google Scholar
• Kang S, Luo R, Smicun Y, et al. Selective induction of cyclooxygenase-2 plays a role in lysophosphatidic acid regulated Fas ligand cell surface presentation. FEBS Lett 2006;580:443–9
   PubMed Web of Science ®Google Scholar
• Meng Y, Graves L, Do TV, et al. Upregulation of FasL by LPA on ovarian cancer cell surface leads to apoptosis of activated lymphocytes. Gynecol Oncol 2004;95:488–95
   PubMed Web of Science ®Google Scholar
• Lee JY, Myung SK, Song YS. Prognostic role of cyclooxygenase-2 in epithelial ovarian cancer: a meta-analysis of observational studies. Gynecol Oncol 2013;129:613–19
   PubMed Web of Science ®Google Scholar
• Uddin S, Ahmed M, Hussain A, et al. Cyclooxygenase-2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer. Int J Cancer 2010;126:382–94
   PubMed Web of Science ®Google Scholar
• Reyners AK, de Munck L, Erdkamp FL, et al. A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study. Ann Oncol 2012;23:2896–902
   PubMed Web of Science ®Google Scholar
• Symowicz J, Adley BP, Woo MM, et al. Cyclooxygenase-2 functions as a downstream mediator of lysophosphatidic acid to promote aggressive behavior in ovarian carcinoma cells. Cancer Res 2005;65:2234–42
   PubMed Web of Science ®Google Scholar
• Oyesanya RA, Lee ZP, Wu J, et al. Transcriptional and post-transcriptional mechanisms for lysophosphatidic acid-induced cyclooxygenase-2 expression in ovarian cancer cells. FASEB J 2008;22:2639–51
   PubMed Web of Science ®Google Scholar
• Jeong KJ, Park SY, Seo JH, et al. Lysophosphatidic acid receptor 2 and Gi/Src pathway mediate cell motility through cyclooxygenase 2 expression in CAOV-3 ovarian cancer cells. Exp Mol Med 2008;40:607–16
   PubMed Web of Science ®Google Scholar
• Worsley SD, Ponder BA, Davies BR. Overexpression of cyclin D1 in epithelial ovarian cancers. Gynecol Oncol 1997;64:189–95
   PubMed Web of Science ®Google Scholar
• Hashimoto T, Yanaihara N, Okamoto A, et al. Cyclin D1 predicts the prognosis of advanced serous ovarian cancer. Exp Ther Med 2011;2:213–19
   PubMed Web of Science ®Google Scholar
• Hu YL, Albanese C, Pestell RG, Jaffe RB. Dual mechanisms for lysophosphatidic acid stimulation of human ovarian carcinoma cells. J Natl Cancer Inst 2003;95:733–40
   PubMed Web of Science ®Google Scholar
• Dobrzycka B, Mackowiak-Matejczyk B, Terlikowska KM, et al. Serum levels of IL-6, IL-8 and CRP as prognostic factors in epithelial ovarian cancer. Eur Cytokine Netw 2013;24:106–13
   PubMed Web of Science ®Google Scholar
• Lane D, Matte I, Rancourt C, Piché A. Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients. BMC Cancer 2011;11:210
   PubMed Web of Science ®Google Scholar
• Duan Z, Foster R, Bell DA, et al. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res 2006;12:5055–63
   PubMed Web of Science ®Google Scholar
• Lo CW, Chen MW, Hsiao M, et al. IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. Cancer Res 2011;71:424–34
   PubMed Web of Science ®Google Scholar
• Coward J, Kulbe H, Chakravarty P, et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 2011;17:6083–96
   PubMed Web of Science ®Google Scholar
• Wang Y, Xu RC, Zhang XL, et al. Interleukin-8 secretion by ovarian cancer cells increases anchorage-independent growth, proliferation, angiogenic potential, adhesion and invasion. Cytokine 2012;59:145–55
   PubMed Web of Science ®Google Scholar
• Wang Y, Qu Y, Niu XL, et al. Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cytokine 2011;56:365–75
   PubMed Web of Science ®Google Scholar
• Schwartz BM, Hong G, Morrison BH, et al. Lysophospholipids increase interleukin-8 expression in ovarian cancer cells. Gynecol Oncol 2001;81:291–300
   PubMed Web of Science ®Google Scholar
• So J, Navari J, Wang FQ, Fishman DA. Lysophosphatidic acid enhances epithelial ovarian carcinoma invasion through the increased expression ofinterleukin-8. Gynecol Oncol 2004;95:314–22
   PubMed Web of Science ®Google Scholar
• Fang X, Yu S, Bast RC, et al. Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem 2004;279:9653–61
   PubMed Web of Science ®Google Scholar
• Chou CH, Wei LH, Kuo ML, et al. Up-regulation of interleukin-6 in human ovarian cancer cell via a Gi/PI3K–Akt/NF-kB pathway by lysophosphatidic acid, an ovarian cancer-activating factor. Carcinogenesis 2005;26:45–52
   PubMed Web of Science ®Google Scholar
• Saunders JA, Rogers LC, Klomsiri C, et al. Reactive oxygen species mediate lysophosphatidic acid induced signaling in ovarian cancer cells. Free Radic Biol Med 2010;49:2058–67
   PubMed Web of Science ®Google Scholar
• Scotton CJ, Wilson JL, Scott K, et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res 2002;62:5930–8
   PubMed Web of Science ®Google Scholar
• Scotton CJ, Wilson JL, Milliken D, et al. Epithelial cancer cell migration: a role for chemokine receptors? Cancer Res 2001;61:4961–5
   PubMed Web of Science ®Google Scholar
• Wang H, Liu W, Wei D, et al. Effect of the LPA-mediated CXCL12-CXCR4 axis in the tumor proliferation, migration and invasion of ovarian cancer cell lines. Oncol Lett 2014;7:1581–5
   PubMed Web of Science ®Google Scholar
• Gunther EC, von Bartheld CS, Goodman LJ, et al. The G-protein inhibitor, pertussis toxin, inhibits the secretion of brain-derived neurotrophic factor. Neuroscience 2000;100:569–79
   PubMed Web of Science ®Google Scholar
• Lee Z, Swaby RF, Liang Y, et al. Lysophosphatidic acid is a major regulator of growth-regulated oncogene A in ovarian cancer. Cancer Res 2006;66:2740–8
   PubMed Web of Science ®Google Scholar
• Hall CA, Wang R, Miao J, et al. Hippo pathway effector yap is an ovarian cancer oncogene. Cancer Res 2010;70:8517–25
   PubMed Web of Science ®Google Scholar
• Cai H, Xu Y. The role of LPA and YAP signaling in long-term migration of human ovarian cancer cells. Cell Commun Signal 2013;11:31
   Google Scholar
• Yu FX, Zhao B, Panupinthu N, et al. Regulation of the Hippo-YAP pathway by G-protein coupled receptor signaling. Cell 2012;150:780–91
   PubMed Web of Science ®Google Scholar
• Jeong GO, Shin SH, Seo EJ, et al. TAZ mediates lysophosphatidic acid-induced migration and proliferation of epithelial ovarian cancer cells. Cell Physiol Biochem 2013;32:253–63
   PubMed Web of Science ®Google Scholar
• Sun H, Ren J, Zhu Q, et al. Effects of lysophosphatidic acid on human colon cancer cells and its mechanisms of action. World J Gastroenterol 2009;15:4547–55
   PubMed Web of Science ®Google Scholar
• Lin CE, Chen SU, Lin CC, et al. Lysophosphatidic acid enhances vascular endothelial growth factor-C expression in human prostate cancer PC-3 cells. PLoS One 2012;7:e41096
   PubMed Web of Science ®Google Scholar
• Hwang YS, Hodge JC, Sivapurapu N, Lindholm PF. Lysophosphatidic acid stimulates PC-3 prostate cancer cell Matrigel invasion through activation of RhoA and NF-kappaB activity. Mol Carcinog 2006;45:518–29
   PubMed Web of Science ®Google Scholar
• Willier S, Butt E, Grunewald TG. Lysophosphatidic acid (LPA) signalling in cell migration and cancer invasion: a focussed review and analysis of LPA receptor gene expression on the basis of more than 1700 cancer microarrays. Biol Cell 2013;105:317–33
   PubMed Web of Science ®Google Scholar
• Hurst JH, Hooks SB. Lysophosphatidic acid stimulates cell growth by different mechanisms in SKOV-3 and Caov-3 ovarian cancer cells: distinct roles for Gi- and Rho-dependent pathways. Pharmacology 2009;83:333–47
   PubMed Web of Science ®Google Scholar
• Okudaira S1, Yukiura H, Aoki J. Biological roles of lysophosphatidic acid signaling through its production by autotaxin. Biochimie 2010;92:698–706
   PubMed Web of Science ®Google Scholar